Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters

Research output: Contribution to journalArticle

109 Citations (Scopus)


Recent antitumor drug research has seen the development of a large variety of tyrosine kinase inhibitors (TKIs) with increasing specificity and selectivity. These are highly promising agents for specific inhibition of malignant cell growth and metastasis. However, their therapeutic potential also depends on access to their intracellular targets, which may be significantly affected by certain ABC membrane transporters. It has been recently shown that several human multidrug transporter ABC proteins interact with specific TKIs, and the ABCG2 transporter has an especially high affinity for some of these kinase inhibitors. These results indicate that multidrug resistance protein modulation by TKIs may be an important factor in the treatment of cancer patients; moreover, the extrusion of TKIs by multidrug transporters may result in tumor cell TKI resistance. Interaction with multidrug resistance ABC transporters may also significantly modify the pharmacokinetics and toxicity of TKIs in patients.

Original languageEnglish
Pages (from-to)15-26
Number of pages12
JournalDrug Resistance Updates
Issue number1-2
Publication statusPublished - Jan 1 2005


  • ABCG2
  • Cancer drug resistance
  • Multidrug transporter
  • Polymorphic variants
  • Xenobiotic transport

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters'. Together they form a unique fingerprint.

  • Cite this